President Donald Trump and Vice President Mike Pence backed the measure. Since the Senate approved similar legislation last August, Republicans could revisit the legislation under rules that would require only a simple majority for passage, perhaps after reworking the measure.
Those strong messages and the support of the White House failed to sway 138 Democrats and two Republicans.More news: Tillerson Thanked Everyone But Trump In His Farewell Speech
"Rather than rush to pass a bill that was hastily unveiled over the weekend without careful consideration or bipartisan consensus, we should work together to find a sensible path forward that protects patients and upholds FDA's approval process while ensuring patients, with no other recourse, have access to investigational therapies", he said. Objections to the bill were underpinned by the belief that it would have little effect on access to medicines but would render patients vulnerable to exploitation by unscrupulous doctors and drugmakers, who would have total control if the FDA was cut out of the process.
Energy and Commerce Committee ranking member Frank Pallone Jr., D-N.J., announced his opposition to the House bill Monday, saying it gives patients "false hope" and puts them at risk by removing the FDA from overseeing use of experimental treatments.
According to the Examiner, right-to-try laws have been passed in 38 states, including in, where then-Governor Mike Pence signed one into law. The FDA would have to be notified of the decision and of any problems that occur.More news: Linda won't be a cyclone for long: Bureau
The House is nearing a vote on a Republican bill easing how experimental drugs are provided to people with terminal illnesses.
"FDA provides helpful information about dosing, or safety monitoring, or something that should be disclosed", she said. Today, patients must get the clearance of a doctor, the manufacturer and the FDA. The House plan narrows the scope of eligible patients to those who are likely to die "within a matter of months" or have a disease that would lead to "significant irreversible morbidity that is likely to lead to severely premature death". Current funding expires on March 23, and House and Senate leaders are hoping to unveil the next spending bill this week.
Alison Bateman House, a bioethicist at New York University, told Politicothat the "right-to-try approach blames an innocent entity for access problems". Its fate is uncertain because it's opposed by top Democrats and scores of patients' groups. They say the more common hurdle is manufacturers, which often prefer to use their limited quantities of early-stage drugs for clinical trials needed to gain final FDA approval for wide-spread sales or worry that a setback could damage the product's marketability.More news: IShares Morningstar Large-Cap Value (JKF) Declines 0.28% for Mar 13